OverviewSuggest Edit

Arcus Biosciences is a biotech company that visions to create new cancer therapeutics through the use of emerging insights in immunology. The Company's lead program targets the adenosine pathway, which has been shown to play a significant role in driving immuno-suppression in the tumor micro-environment. Like IDO inhibitors, adenosine receptor antagonists and inhibitors of adenosine production are expected to be highly synergistic with other immuno-oncology mechanisms, as well as with chemotherapy. Because of the promise of the adenosine pathway, several adenosine receptor antagonists that were discovered years ago and initially developed for other indications have been repurposed for oncology.

Arcus has generated novel, small- molecule dual antagonists of key adenosine receptors A2aR and A2bR. The Company believes that its lead molecule, AB928, will be the first clinical compound that was designed specifically for its immune-stimulating properties.  Arcus has other product candidates in earlier stages of development that target the adenosine pathway, including a CD73 inhibitor (which blocks the generation of extracellular adenosine in tumors) that could be the first small-molecule inhibitor of CD73 to enter clinical trials.

TypePublic
Founded2015
HQHayward, CA, US
Websitearcusbio.com
Employee Ratings4.6

Latest Updates

Employees (est.) (Feb 2019)83
Job Openings56
Revenue (FY, 2017)$1.4 M
Share Price (Jun 2021)$25(+2%)
Cybersecurity ratingBMore

Key People/Management at Arcus Biosciences

Juan Jaen

Juan Jaen

President
Terry Rosen

Terry Rosen

CEO
Jennifer Jarrett

Jennifer Jarrett

Chief Operating Officer
Carolyn Tang

Carolyn Tang

General Counsel
William J. Grossman

William J. Grossman

Chief Medical Officer
Jay Powers

Jay Powers

SVP, Drug Discovery
Show more

Arcus Biosciences Office Locations

Arcus Biosciences has an office in Hayward
Hayward, CA, US (HQ)
3928 Point Eden Way
Show all (1)

Arcus Biosciences Financials and Metrics

Arcus Biosciences Revenue

Arcus Biosciences's revenue was reported to be $1.41 m in FY, 2017
USD

Revenue (FY, 2017)

1.4m

Net income (FY, 2017)

(53.1m)

EBIT (FY, 2017)

(53.4m)

Market capitalization (4-Jun-2021)

1.8b

Closing stock price (4-Jun-2021)

25.0

Cash (31-Dec-2017)

98.4m
Arcus Biosciences's current market capitalization is $1.8 b.
USDFY, 2016FY, 2017

Revenue

1.4m

General and administrative expense

3.9m7.6m

R&D expense

14.2m47.2m

Operating expense total

18.2m54.9m
USDFY, 2016FY, 2017

Cash

65.2m98.4m

Prepaid Expenses

390.0k1.1m

Current Assets

99.7m176.9m

PP&E

8.6m11.2m
USDFY, 2016FY, 2017

Net Income

(18.0m)(53.1m)

Depreciation and Amortization

1.3m2.6m

Accounts Payable

3.6m(267.0k)

Cash From Operating Activities

(12.9m)(25.1m)
USDFY, 2016

Financial Leverage

1.1 x
Show all financial metrics

Arcus Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Arcus Biosciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

CSRHub logo

Arcus Biosciences Online and Social Media Presence

Embed Graph

Arcus Biosciences News and Updates

Gilead buys more Arcus Biosciences stock, at a price above the record close

Arcus Biosciences Inc. disclosed Monday that Gilead Sciences Inc. boosted its stake in the oncology-focused biopharmaceutical company, through the purchase of $220.35 million worth of stock. Arcus shares were still inactive in premarket trading. Under terms of the stake increase, Gilead bought 5.6…

BRIEF-James Tananbaum Reports 9.6 PCT Passive Stake In Arcus Biosciences Inc As Of March 14

* JAMES TANANBAUM REPORTS 9.6 PERCENT PASSIVE STAKE IN ARCUS BIOSCIENCES INC AS OF MARCH 14, 2018 - SEC FILING‍​ Source text - https://bit.ly/2pEVSbN Further company coverage:

Arcus Biosciences Blogs

Adenosine dreams fueling new approaches in cancer; Arcus embarks on phase I

The post Adenosine dreams fueling new approaches in cancer; Arcus embarks on phase I appeared first on Arcus Biosciences.

Arcus Biosciences to Participate in the 2018 Wedbush PacGrow Healthcare Conference

The post Arcus Biosciences to Participate in the 2018 Wedbush PacGrow Healthcare Conference appeared first on Arcus Biosciences.

Arcus Biosciences Announces Initiation of Phase 1 Trial for AB154, its Anti-TIGIT Antibody

The post Arcus Biosciences Announces Initiation of Phase 1 Trial for AB154, its Anti-TIGIT Antibody appeared first on Arcus Biosciences.

Arcus Biosciences Announces Final Safety Results From Phase 1 Trial for AB928 in Healthy Volunteers

The post Arcus Biosciences Announces Final Safety Results From Phase 1 Trial for AB928 in Healthy Volunteers appeared first on Arcus Biosciences.

Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories

The post Arcus Biosciences Announces That Taiho Pharmaceutical Has Exercised Its Option to Develop and Commercialize AB928 in Its Territories appeared first on Arcus Biosciences.

Arcus Biosciences Announces the Promotion of Jennifer Jarrett to Chief Operating Officer

The post Arcus Biosciences Announces the Promotion of Jennifer Jarrett to Chief Operating Officer appeared first on Arcus Biosciences.
Show more

Arcus Biosciences Frequently Asked Questions

  • When was Arcus Biosciences founded?

    Arcus Biosciences was founded in 2015.

  • Who are Arcus Biosciences key executives?

    Arcus Biosciences's key executives are Juan Jaen, Terry Rosen and Jennifer Jarrett.

  • How many employees does Arcus Biosciences have?

    Arcus Biosciences has 83 employees.

  • What is Arcus Biosciences revenue?

    Latest Arcus Biosciences annual revenue is $1.4 m.

  • What is Arcus Biosciences revenue per employee?

    Latest Arcus Biosciences revenue per employee is $17 k.

  • Who are Arcus Biosciences competitors?

    Competitors of Arcus Biosciences include Taiho Pharmaceutical, Spectrum Pharmaceuticals and Progenics Pharmaceuticals.

  • Where is Arcus Biosciences headquarters?

    Arcus Biosciences headquarters is located at 3928 Point Eden Way, Hayward.

  • Where are Arcus Biosciences offices?

    Arcus Biosciences has an office in Hayward.

  • How many offices does Arcus Biosciences have?

    Arcus Biosciences has 1 office.